Search

Your search keyword '"Antineoplastic agents -- Marketing"' showing total 212 results
Start Over Descriptor "Antineoplastic agents -- Marketing"
212 results on '"Antineoplastic agents -- Marketing"'

1. Reports from Jilin University Advance Knowledge in Anticancer Agents (Polysulfonium: Unveiling a Bioactive Polymer To Induce Immunogenic Cell Death for Anticancer Therapy)

Subjects
Biochemistry, Cell death, Antineoplastic agents -- Marketing, Immune response, Cancer -- Care and treatment, Physical fitness, Antimitotic agents -- Marketing, Company marketing practices, Health
Abstract

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Anticancer Agents. According [...]

Published
2024

3. Zydus Lifesciences launches cancer drug - IBYRA in India

Subjects
Antineoplastic agents -- Marketing, Pancreatic cancer -- Drug therapy, Antimitotic agents -- Marketing, Company marketing practices, News, opinion and commentary
Abstract

In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target [...]

Published
2024

5. MSN launches generic version of breast cancer drug

Subjects
Online information services -- Marketing, Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Online services -- Marketing, Information services -- Marketing, Breast cancer, Antimitotic agents -- Marketing, Company marketing practices, Online information service, News, opinion and commentary
Abstract

January 18 -- MSN Group launched the `world’s first’ generic Palbociclib tablets indicated for advanced breast cancer therapy under the brand Palborest. While there are few other companies set to [...]

Published
2023

6. BDR Pharma launches first generic apalutamide to treat prostate cancer in India

Subjects
Prostate cancer -- Development and progression -- Care and treatment, Metastasis -- Care and treatment -- Development and progression, Antineoplastic agents -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau BDR Pharmaceutical has launched the first generic apalutamide (brand name Apatide) in India to treat both metastatic castration sensitive prostate cancer as well as non-metastatic castration resistant [...]

Published
2023

7. The European Medicines Agency confirms the admissibility of the marketing authorization application file submitted by Laboratoires Pierre Fabre for BRAFTOVI(r) (encorafenib) administered in combination with MEKTOVI(r) (binimetinib) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with BRAFV600 mutation

Subjects
Gene mutations -- Genetic aspects, Antineoplastic agents -- Marketing, Lung cancer, Small cell -- Genetic aspects, Lung cancer, Non-small cell -- Genetic aspects, Marketing, Antimitotic agents -- Marketing, Company marketing practices, General interest, News, opinion and commentary, Braftovi (Medication) -- Marketing, Mektovi (Medication) -- Marketing
Abstract

CASTRES: Pierre Fabre has issued the following press release: Pierre Fabre Laboratories announced today that the European Medicines Agency (EMA) has confirmed the admissibility of the marketing authorization application file [...]

Published
2023

8. Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis

Subjects
Women -- Health aspects, Antineoplastic agents -- Marketing, Pituitary hormones, Endometriosis, Antimitotic agents -- Marketing, Company marketing practices, Health, Women's issues/gender studies
Abstract

2021 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Debiopharm ( www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian [...]

Published
2021

9. EMA grants conditional marketing authorization to Kite's Tecartus to treat relapsed/refractory mantle cell lymphoma

Subjects
T cells, Antineoplastic agents -- Marketing, Non-Hodgkin's lymphomas, Drug approval, Marketing, Antimitotic agents -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Kite, a Gilead Company announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T [...]

Published
2020

10. Shilpa Medicare launches generic axitinib to treat advanced renal cell carcinoma

Subjects
Antineoplastic agents -- Marketing, Carcinoma, Renal cell -- Care and treatment, Antimitotic agents -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau In continuation to its recent launches of three products in the cancer therapy, Lenvatinib 'Lenshil Dasatinib 'Dasashil' and Ibrutinib 'Ibrushil' in Indian market, Shilpa Medicare Limited launches [...]

Published
2020

11. Natco Pharma launches cancer drug - Tipanat in India

Subjects
Antineoplastic agents -- Marketing, Stomach cancer -- Drug therapy, Trifluridine -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, News, opinion and commentary
Abstract

Natco Pharma has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first-time in India under the brand name Tipanat as a pack of 20 tablets in a [...]

Published
2021

12. NATCO launches cancer drug Tipanat in India

Subjects
Antineoplastic agents -- Marketing, Stomach cancer -- Drug therapy, Trifluridine -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Biotechnology industry
Abstract

The drug is indicated for the treatment of advanced colorectal and gastric cancer Natco Pharma has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first time in [...]

Published
2021

13. Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis

Subjects
Antineoplastic agents -- Marketing, Pituitary hormones, Estrogen, Endometriosis, Antimitotic agents -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch [...]

Published
2021

14. Marketing personalized cancer treatments requires careful language

Subjects
Antineoplastic agents -- Marketing, Tumors, Marketing, Cancer treatment, Cancer cells, Television programs, Company marketing practices, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Therapies tailored to individual tumours must not be oversold.Therapies tailored to individual tumours must not be oversold., Author Affiliations:Marketing personalized cancer treatments requires careful language Precision oncology matches drugs to tumour type but will not work for everybody. [see PDF for image]Coloured SEM of prostate cancer cellsCancer [...]

Published
2018
Full Text
View/download PDF

15. CrystalGenomics hopes to launch pancreatic cancer drug early next year

Subjects
Pancreatic cancer -- Drug therapy, Antineoplastic agents -- Marketing, Company marketing practices, Business, international, Law
Abstract

CrystalGenomics is hoping to launch its investigational pancreatic cancer early next year under conditional marketing authorization, Cho Joong-myung, the founder and chairman of the Korean biotech firm told Maeil Business [...]

Published
2020

16. BDR Pharma launches generic cancer drug in India

Subjects
Thyroid cancer -- Care and treatment, Liver cancer -- Care and treatment, Generic drugs -- Marketing, Lenvatinib, Antineoplastic agents -- Marketing, Company marketing practices, Business, international, Law
Abstract

BDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers in India. The generic version of the drug [...]

Published
2020

17. Targeting bone health: reducing complications of prostate cancer from the satellite symposium at the Southeastern Section of the AUA Annual Meeting

Author

Crawford, E. David and Shore, Neal D.

Subjects
Company marketing practices, Metastasis -- Conferences, meetings and seminars, Metastasis -- Care and treatment, Metastasis -- Complications and side effects, Continuing medical education -- Conferences, meetings and seminars, Prostate cancer -- Conferences, meetings and seminars, Prostate cancer -- Care and treatment, Prostate cancer -- Complications and side effects, Antimitotic agents -- Conferences, meetings and seminars, Antimitotic agents -- Complications and side effects, Antimitotic agents -- Marketing, Antineoplastic agents -- Conferences, meetings and seminars, Antineoplastic agents -- Complications and side effects, Antineoplastic agents -- Marketing, Cancer -- Care and treatment, Cancer -- Conferences, meetings and seminars
Abstract

Content Source This continuing medical education (CME) supplement is based on a CME satellite symposium discussion held in Rio Grande, Puerto Rico, on March 4, 2006, at the Southeastern Section [...]

Published
2006

18. Maximizing returns

Author

Morrissey, Susan R.

Subjects
United States. National Institutes of Health -- Product development, United States. National Institutes of Health -- Marketing, United States. National Institutes of Health -- Contracts, Bristol-Myers Squibb Co. -- Marketing, Bristol-Myers Squibb Co. -- Contracts, Antineoplastic agents -- Product development, Antineoplastic agents -- Marketing, Antineoplastic agents -- Contracts, Antimitotic agents -- Product development, Antimitotic agents -- Marketing, Antimitotic agents -- Contracts, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Contracts, Pharmaceutical industry -- Product development, Cooperative agreement for product marketing, Chemicals, plastics and rubber industries, Engineering and manufacturing industries, Taxol (Medication) -- Product development, Taxol (Medication) -- Marketing, Taxol (Medication) -- Contracts
Abstract

Taxol is a powerful anticancer drug that was discovered by the National Institutes of Health's National Cancer Institute. Florida State university later developed a semisynthesis method for producing Taxol. Yet, Bristol-Myers Squibb is marketing it through a Cooperative Research & Development Agreement. Congress is concerned that such agreements do not always benefit taxpayers.

Published
2003

19. Toward better quality of anticancer generics in India

Author

Gota, V. and Patial, P.

Subjects
Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Antimitotic agents -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Health
Abstract

Byline: V. Gota, P. Patial Treatment of cancer is limited by affordability of patients in the many developing countries including India. Generic drug manufacturers have responded to this scenario by [...]

Published
2014

20. Largest US drug distributor accused of illegally handling cancer medication

Author

Bernstein, Lenny

Subjects
McKesson Corp. -- Cases -- Marketing -- Subsidiaries, divisions and units, Damages (Law) -- Cases, Pharmaceutical industry -- Cases -- Marketing -- Subsidiaries, divisions and units, Antineoplastic agents -- Marketing, Company legal issue, Company marketing practices, General interest, News, opinion and commentary
Abstract

Byline: Lenny Bernstein One of the nation's largest drug distributors is being accused of illegally pooling leftover cancer medication from single-dose vials and selling it to health-care providers, who treated [...]

Published
2018

21. ELI LILLY ENTERS BRANDED GENERICS, LAUNCHES FOUR CANCER DRUGS (the company intends to play a leading role in fighting cancer in India)

Subjects
Eli Lilly and Co. -- Marketing, Antineoplastic agents -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Banking, finance and accounting industries, Business, Business, international, News, opinion and commentary
Abstract

Eli Lilly has entered the branded generics business in India. The company has launched Lilbecep, Lilmantro, Lilxapla and Lilrincan for the treatment of breast and colo-rectal cancer. Eli Lilly intends [...]

Published
2013

22. Researchers at Capital Normal University Target Cancer (DNA-templated porous nanoplatform towards programmed 'double-hit' cancer therapy via hyperthermia and immunogenicity activation)

Subjects
Cancer treatment, Cancer genetics, Genetic research, Cancer, Cancer research, Biochemistry, DNA, Fever, Antineoplastic agents -- Marketing, Medical practice, Education, Teachers, Tumors, Editors, Novels, Company marketing practices, Business, Health, Health care industry
Abstract

2019 SEP 3 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Cancer have been published. According to news reporting originating from Beijing, [...]

Published
2019

23. JAPAN'S EISAI TO LAUNCH BREAST CANCER DRUG HERE (will launch its novel anti-cancer drug Eribulin in India)

Subjects
Antineoplastic agents -- Marketing, Breast cancer -- Care and treatment, Antimitotic agents -- Marketing, Company marketing practices, Banking, finance and accounting industries, Business, Business, international, News, opinion and commentary
Abstract

Pharmaceutical company Eisai Pharma of Japan will launch its novel anti-cancer drug Eribulin in India. This is part of the company's strategy to expand its presence in emerging markets. The [...]

Published
2013

24. Indian firm caught marketing anticancer drug for fertility

Author

Sharma, Dinesh C

Subjects
Pharmaceutical industry -- Marketing, Antineoplastic agents -- Marketing, Antimitotic agents -- Marketing, Infertility, Female -- Drug therapy, Company marketing practices, Sun Pharmaceuticals Industries Ltd. -- Product information, Sun Pharmaceuticals Industries Ltd. -- Marketing
Published
2003

25. Generic blood cancer drug launched by Natco

Subjects
Generic drugs -- Marketing, Multiple myeloma -- Development and progression -- Drug therapy, Antineoplastic agents -- Marketing, Company marketing practices, Biotechnology industry
Abstract

Natco Pharma will market generic pomalidomide capsules under its brand name Pomalid in India. Natco Pharma has launched a generic version of pomalidomide capsules, used in treatment of a type [...]

Published
2017

26. PUNE FIRM ROLLS OUT LOW-COST CANCER DRUG (the company will sell PEGEX at Rs17,900 against Rs27,000 charged by the other brands)

Subjects
Antineoplastic agents -- Marketing, Cancer -- Care and treatment, Brand name products, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Banking, finance and accounting industries, Business, Business, international, News, opinion and commentary
Abstract

Gennova Biopharmaceuticals, a 100 percent subsidiary of Emcure Pharmaceuticals of Pune, has commercially launched the cancer drug Pegfilgrastim (PEGEX) in India. The drug is expected to reduce the duration of [...]

Published
2010

27. Novartis Seeks Indication for Letrozole in Adjuvant Treatment of Early Breast Cancer

Subjects
Company marketing practices, Novartis AG -- Product development, Femara (Medication) -- Licensing, certification and accreditation, Femara (Medication) -- Marketing, Breast cancer -- Drug therapy, Antimitotic agents -- Marketing, Antineoplastic agents -- Marketing, Pharmaceutical industry -- Product development
Abstract

Novartis has submitted marketing authorization applications in the United States and Europe for the use of letrozole (Femara) in the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast [...]

Published
2005

28. SuperGen affiliate files for European approval of mitomycin

Subjects
EuroGen Pharmaceuticals -- Marketing, SuperGen Inc. -- Foreign operations -- Marketing, Antineoplastic agents -- Marketing, Mitomycin -- Marketing, Antimitotic agents -- Marketing, Testolactone, Pharmaceutical industry -- Marketing -- Foreign operations, Company marketing practices, Health, Women's issues/gender studies
Abstract

2002 OCT 31 - (NewsRx.com & NewsRx.net) -- SuperGen, Inc., (SUPG) announced that its European affiliate, EuroGen Pharmaceuticals, Ltd., has filed a mutual recognition application with the medicines control agency [...]

Published
2002

29. Tentative approval granted for anticancer compound carboplatin

Subjects
Company marketing practices, American Pharmaceutical Partners Inc. -- Marketing, Carboplatin -- Marketing, Antineoplastic agents -- Marketing, Antimitotic agents -- Marketing
Abstract

2002 JUL 11 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners (APPX) announced it has received tentative approval from the U.S. Food and Drug Administration (FDA) of its abbreviated new [...]

Published
2002

30. FDA approval granted for generic paclitaxel

Subjects
Company marketing practices, NaPro BioTherapeutics Inc. -- Marketing, Abbott Laboratories (Abbott Park, Illinois) -- Marketing, Antineoplastic agents -- Marketing, Ovarian cancer -- Drug therapy, Breast cancer -- Drug therapy, Paclitaxel -- Marketing, Antimitotic agents -- Marketing
Abstract

2002 JUL 11 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) and NaPro BioTherapeutics, Inc., (NPRO) announced that they have received approval from the U.S. Food and Drug Administration (FDA) [...]

Published
2002

31. Stock Watch: Biotechnology firms engineer surge; Despite higher flows of red ink, shares of Emisphere and OSI rebound

Author

Harrington, John

Subjects
Emisphere Technologies Inc. -- Finance, OSI Pharmaceuticals Inc. -- Finance, Pharmaceutical industry -- Finance, Antineoplastic agents -- Marketing, Business, Business, regional
Abstract

Though most biotechnology companies have yet to turn profitable, investors are looking past the present and deep into what they expect will be a gilded future. So far this month, [...]

Published
2001

32. ENTREMED

Author

MADIGAN, SEAN

Subjects
EntreMed Inc. -- Product information, Royalty Pharma AG -- Marketing, Pharmaceutical industry -- Product information, Thalidomide -- Marketing, Cancer -- Drug therapy, Antineoplastic agents -- Marketing, Business, Business, regional
Abstract

ENTREMED cashed out Aug. 8, selling its rights to future royalties from the sales of thalidomide to Swiss drug makers ROYALTY PHARMA for $24.3 million. Remarketed as a cancer-fighting therapy [...]

Published
2001

33. Hoffmann-La Roche

Subjects
Hoffmann-La Roche Inc. -- Marketing, Colorectal cancer -- Metastasis, Metastasis, Antineoplastic agents -- Marketing, Business, Health, Health care industry, Pharmaceuticals and cosmetics industries, Xeloda (Medication) -- Marketing
Published
2001

34. Novartis Pharmaceuticals Corp

Subjects
Novartis Pharmaceuticals Corp. -- Marketing, Chronic myeloid leukemia, Antineoplastic agents -- Marketing, Business, Health, Health care industry, Pharmaceuticals and cosmetics industries, Gleevec (Medication) -- Marketing
Published
2001

35. Roche

Subjects
Roche Holding AG -- Product information, Pharmaceutical industry -- Product information, Colorectal cancer, Antineoplastic agents -- Marketing, Business, Chemicals, plastics and rubber industries, Xeloda (Medication) -- Marketing
Published
2001

36. Studies from Eli Lilly and Company Further Understanding of Non-Small Cell Lung Cancer [Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)]

Subjects
Eli Lilly and Co. -- Marketing, Cancer research, Marketing, Small cell lung cancer, Lung diseases, Pharmaceutical industry -- Marketing, Non-small cell lung cancer, Antineoplastic agents -- Marketing, Company marketing practices, Advertising, marketing and public relations
Abstract

2017 JUN 10 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Investigators publish new report on Oncology - Non-Small Cell Lung Cancer. According to news [...]

Published
2017

37. Ex-Bayer exec aims at cancer

Author

Leuty, Ron

Subjects
Bayer HealthCare L.L.C. -- Licensing agreements, Oral medication -- Product information, Oral medication -- Product development, Oral medication -- Marketing, Pharmaceutical industry -- Licensing agreements, Pharmaceutical industry -- Officials and employees, Antimitotic agents -- Product development, Antimitotic agents -- Marketing, Antineoplastic agents -- Product development, Antineoplastic agents -- Marketing, Company marketing practices, Company licensing agreement, Product marketing strategy, Business, Business, regional
Abstract

ACT Biotech Inc. has signed a licensing deal with Bayer Healthcare to develop and market oral cancer drugs. Bayer's cost-cutting efforts and facility closure in West Haven, Connecticut led ACT chief executive officer Wolf Busse to align ACT Biotech's strategies based on Bayer's surplus compounds. ACT Biotech's financial details, products and planned partnerships are also discussed.

Published
2008

38. Cephalon receives subpoena in off-label marketing investigation

Subjects
United States. Securities and Exchange Commission -- Investigations, Cephalon Inc. -- Marketing, Antineoplastic agents -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company legal issue, Company marketing practices, Business, General interest, Business, regional
Abstract

Byline: David Sell Sept. 27--Cephalon Inc. is under investigation again for alleged off-label marketing of a drug. The Frazer-based pharmaceutical company told the Securities and Exchange Commission in a filing [...]

Published
2011

39. Cephalon receives subpoena in off-label marketing investigation

Subjects
United States. Securities and Exchange Commission -- Investigations, Cephalon Inc. -- Marketing, Antineoplastic agents -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company legal issue, Company marketing practices, Business, General interest, Business, regional
Abstract

Byline: David Sell Sept. 26--Cephalon Inc., is under investigation again for alleged off-label marketing of a drug. The Frazer-based pharmaceutical company told the Securities and Exchange Commission in a filing [...]

Published
2011

40. Galena Promoting Experimental Breast Cancer Drug With Faux News Articles Again

Subjects
United States. Securities and Exchange Commission, Antineoplastic agents -- Marketing, Cancer -- Care and treatment, Sulfur compounds -- Marketing, Breast cancer, Antimitotic agents -- Marketing, Company marketing practices, Business
Abstract

Byline: Adam Feuerstein To view this article on the web, click here: http://www.thestreet.com/story/12743908/1/galena-promoting-experimental-breast-cancer-drug-with-faux-news-articles-again.html As we all know, the Securities and Exchange Commission is investigating (http://www.thestreet.com/story/12532765/1/galena-discloses-sec-investigation-focused-on-stock-touting-campaign.html) Galena Biopharma (GALE) for its [...]

Published
2014

41. Eli Lilly enters branded generics; launches four cancer drugs

Subjects
Eli Lilly and Co. -- Marketing, Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

Eli Lilly launched expanded its oncology division and launched Lil Therapeutics to deliver affordable cancer drugs to Indian patients. Four branded generic drugs for treatment of breast and colorectal cancer [...]

Published
2013

42. Eli Lilly launches four new cancer drugs

Subjects
Eli Lilly and Co. -- Marketing, Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

On 10 Dec 2013, US-based Eli Lilly's subsidiary Eli Lilly and Company India introduced to the market Lil Therapeutics, a branded generics segment under its oncology division. India is the [...]

Published
2013

43. Sales of Genentech's Cancer Drug Climb

Subjects
Company marketing practices, Company business forecast/projection, Company earnings/profit, Roche Holding AG -- Company forecasts -- Company sales and earnings -- Marketing, Avastin (Medication) -- Marketing, Antineoplastic agents -- Marketing, Antimitotic agents -- Marketing, Pharmaceutical industry -- Company sales and earnings -- Company forecasts
Abstract

Genentech reported on Tuesday that sales of its cancer drug Avastin topped Wall Street estimates, even though third-quarter earnings fell short of analyst expectations because of higher costs. Sales in […]

Published
2008

44. AZ suspends marketing of cancer drug PHARMACEUTICALS

Author

Jack, Andrew

Subjects
Antimitotic agents -- Marketing, Antineoplastic agents -- Marketing, Cancer, Company marketing practices, Banking, finance and accounting industries, Business, Business, international
Abstract

AstraZeneca, the Anglo-Swedish pharmaceutical group, suffered another setback when it suspended marketing of Iressa, a lung cancer drug launched this year. The company said it was in discussions with regulators [...]

Published
2004

45. Assessing the market for cytotoxic drugs

Author

Laker, Thomas L.

Subjects
Pharmaceutical industry -- Marketing, Antineoplastic agents -- Marketing, Advertising, marketing and public relations, Business, Health care industry
Abstract

Assessing the market for cytotoxic drugs In terms of market evaluation and business and product planning, the 'oncology market' provides a great challenge. That conclusion comes from over 20 years' [...]

Published
1989

46. Biocon gets India marketing rights for Roche's cancer drug clone; The cancer drug has market of around $6 billion globally

Subjects
Biological products -- Marketing, Antineoplastic agents -- Marketing, Marketing, Antimitotic agents -- Marketing, Company marketing practices, Business, international
Abstract

Biocon, Asia's leading biotechnology enterprise, has reportedly received India marketing rights for Roche's cancer drug clone. The cancer drug has market of around $6 billion globally. Moreover, the company is [...]

Published
2013

47. Japan's Eisai to launch breast cancer drug in India

Subjects
Antineoplastic agents -- Marketing, Breast cancer, Antimitotic agents -- Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

As part of the plan to promote itself in emerging markets, Japan-based Eisai Pharma intends to introduce its anticancer drug Eribulin, marketed under the brand name 'Halaven', in India. The [...]

Published
2013

48. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market

Subjects
Bayer AG -- Marketing, Eli Lilly and Co. -- Marketing, Sanofi S.A. -- Marketing, Antineoplastic agents -- Marketing, Colorectal cancer, Cancer -- Care and treatment, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Increased Incidence and the Launches of Premium-Priced Agents Will Sustain Four Percent Annual Growth in the Turkish Market, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 25, [...]

Published
2013

49. Teva Pharmaceuticals and Perrigo Co announce the US launch of generic temozolomide

Subjects
Perrigo Co. -- Marketing, Teva Pharmaceutical Industries Ltd. -- Marketing, Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Pharmaceutical industry -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

Teva Pharmaceutical Industries Ltd (Teva Pharmaceutical) and Perrigo Co announced the launch of the generic equivalent to Temodar (temozolomide). Teva Pharmaceutical will manufacture, market and distribute the product in the [...]

Published
2013

50. PropThink: SGNT Generic Leucovorin Launches; SPPI Should Absorb The News Well

Subjects
Thomson Reuters Corp. -- Marketing, Antineoplastic agents -- Marketing, Generic drugs -- Marketing, Information services industry -- Marketing, Leucovorin -- Marketing, Information services -- Marketing, Antimitotic agents -- Marketing, Company marketing practices, Information services industry, Business, international
Abstract

(Thomson Reuters ONE via COMTEX) -- By David Moskowitz Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been under pressure as investors await the supply of generic leucovorin to increase and compete [...]

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results